| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 177.78% | Maxim Group | → $1.5 | Upgrades | Hold → Buy |
| 05/16/2023 | 2862.96% | Ladenburg Thalmann | $25 → $16 | Maintains | Buy |
| 03/30/2023 | 9159.26% | Maxim Group | → $50 | Upgrades | Hold → Buy |
| 08/19/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 02/02/2022 | 825.93% | Ladenburg Thalmann | → $5 | Initiates Coverage On | → Buy |
| 08/31/2021 | 1196.3% | Maxim Group | → $7 | Initiates Coverage On | → Buy |
What is the target price for Palisade Bio (PALI)?
The latest price target for Palisade Bio (NASDAQ: PALI) was reported by Maxim Group on November 17, 2023. The analyst firm set a price target for $1.50 expecting PALI to rise to within 12 months (a possible 177.78% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Palisade Bio (PALI)?
The latest analyst rating for Palisade Bio (NASDAQ: PALI) was provided by Maxim Group, and Palisade Bio upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Palisade Bio (PALI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Palisade Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Palisade Bio was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Palisade Bio (PALI) correct?
While ratings are subjective and will change, the latest Palisade Bio (PALI) rating was a upgraded with a price target of $0.00 to $1.50. The current price Palisade Bio (PALI) is trading at is $0.54, which is within the analyst's predicted range.